According to the offering prospectus, of the 22,733,424 shares to be registered in the Commercial Register, 6,865,650, or 30% of the company's outstanding stock, were offered to the public. Should the underwriters elect to exercise their green-shoe option, that proportion could rise to 34%. 4,085,000 of the publicly offered shares were part of a capital increase associated with the IPO.
JOMED N.V. with its headquarter in Amsterdam (Netherlands), is a medical technology company which develops, produces and distributes products such as stents and balloon catheters for the market of vascular medicine. In addition the company is developing new products for cardiac assist and minimally invasive cardiovascular surgery.
JOMED N.V. founded in 1991 employs 400 individuals and markets its products in over 60 countries. The company recorded in 1999 revenues of USD 44 million and a net profit of USD 2 million.
